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Background: Increasingly, the role of chronic inflammation and its mediators in tumor generation and progression
is gaining importance in the field of cancer research. In this context, candidature of non steroidal anti-inflammatory
drugs (NSAIDs) as potential anti-tumor therapeutic agent is being evaluated globally. In the present study we have
evaluated the anti-cancer effect of a series of newly synthesized naproxen derivatives on human breast cancer cell
lines.
Methods: MCF-7 (poorly invasive) and MDA-MB-231 (highly invasive) cells were treated with different concentrations
of naproxen sodium and its derivatives in vitro, and the underlying mechanism of action was monitored by employing
studies related to induction of apoptosis, activation of caspases, cell-cycle progression, synthesis of PGE2 and cellular
migration.
Results: After a preliminary screening using MCF-7 and MDA-MB-231 cells, it was evident that naproxen derivative 4
has a better killing property compared to its parent compound naproxen sodium (NS). On further investigation, it was
apparent that the observed growth inhibitory activity on MDA-MB-231 cells after treatment with 4, was not due to cell
cycle arrest but due to an early induction of apoptosis and subsequent induction of caspases 3 and 9. Derivative 4
could also inhibit COX activity in MDA-MB-231 cells as evidenced by reduction in prostaglandin E2 secretion. Moreover,
4 was capable of delaying the overall migration rate of MDA-MB-231 cells in vitro.
Conclusion: In this study we report that a naproxen-derivative (4) has powerful anti-inflammatory and anti-tumor
properties as it induces appreciable amount of apoptosis in breast cancer cell line, and can also delay migration of
cancer cells (MDA-MB-231) which would in turn delay cancer cell invasion and formation of secondary tumours in
primary breast cancer patients. Thus, we propose that 4 is worthy of further investigation due to its potential as a
therapeutic agent in anti-tumor treatment regimen.
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The functional relationship between inflammation and
cancer was first brought into picture in 1863, when Rudolf
Virchow hypothesized that cancer originates at the site
of chronic inflammation [1]. Since then a vast number of
studies have emphasized on the role of chronic inflam-
mation in tumorogenesis [2] and potential use of non-
steroidal anti-inflammatory drugs (NSAID) as anti-cancer* Correspondence: bcjd@iacs.res.in; bcssj@iacs.res.in
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unless otherwise stated.agents [3-5]. Although gastrointestinal bleeding and in-
creased cardiovascular (CV) problems are associated with
most of the known NSAIDs, naproxen is known for its
fewer CV effects with a possible cardioprotective role in
human [6]. In a phase II clinical trial, naproxen was found
to be safe and effective in treating progressive prostate
cancer with early recurrent disease [7] and a recent study
using a murine model of induced colon cancer, has also
indicated the anti-cancer properties of this drug [8].
The molecular mechanisms, by which NSAIDs impart
their chemopreventive effects, are a matter of intense de-
bate till date. The most accepted hypothesis has focused. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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by cyclooxygenase (COX-1 and −2) inhibition [9]. Over
expression of COX-2 [10] along with increased levels of
prostaglandin E2 (PGE2) in breast cancer patients have
been reported [11]. It is of note that PGE2, a known COX-
2-derived prostaglandin, plays a significant role in progres-
sion and metastasis of cancer cells by modulating local
tumor microenvironment [12]. Hence, molecules with an
enhanced capacity to reduce PGE2 in cancer cells are of
great interest.
To demonstrate the above hypothesis we chose to
work with four naproxen-derivatives [13] 1–4 (Figure 1).
In the present study we report that naproxen derivative
4 can be employed as an anti-cancer agent due to its en-
hanced cytotoxic activity against human breast cancer
cell lines and also address the underlying mechanism of
action by employing studies related to induction of apop-
tosis, activation of caspases, cell-cycle progression, synthe-
sis of PGE2 and cellular migration.
Methods
Synthesis of naproxen derivatives (1–4)
All the naproxen derivatives were synthesized according
to the methods described in our previously published lit-
erature [13].
Cell culture
The human breast cancer cell line MCF-7 and the mouse
macrophage RAW 264.7 cells were cultured in high glu-
cose Dulbecco's minimal essential medium (DMEM) sup-
plemented with 10% FBS (Life Technologies) and 1%Figure 1 Naproxen and its derivatives (1–4).L-glutamine-penicillin-streptomycin (Life Technologies)
and Insulin (in case of MCF-7), and maintained in a hu-
midified incubator at 37°C and 5% CO2. MDA-MB-231, a
rather aggressive form of human breast cancer cell line,
was grown in Leibovitz's L-15 medium in presence of 10%
fetal bovine serum and antibiotics, penicillin and strepto-
mycin and required a 37°C incubator with 100% air envir-
onment for optimum growth. They grew as a monolayer
in the culture plate and were regularly passaged at ~80%
confluency.
Cell lines were purchased from ATCC (American Type
Culture Collection, Manassas, VA, USA) and maintained
in our cell culture facility.
MTT assay
Briefly, 104 cells/well were seeded in a 96-well plate and
left to adhere overnight. Compounds were prepared as
a stock (50 mM) in DMSO-media, prior to addition to
the cells. The culture medium was replaced with medium
containing the compounds at various concentrations
(1 mM, 3 mM, 5 mM, 10 mM) and incubated for
another 24 h following addition of 100 μl of 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT; 1 mg/ml) stain per well, incubated for 3 h at 37°C
and subjected to DMSO (150 μl/well). Incubation was car-
ried out further for another 10 min at 37°C, and the ab-
sorbance was recorded at 570 nm using a plate reader
(VARIOSKAN, ThermoFisher).Figure 2 Derivative 4 induces caspase 3/9 activation. MDA-MB-231
cells were left untreated or treated with NS and 4 for 6 h, and cell
lysates were prepared. The lysates were then incubated with substrates
of caspase 8, 9 and 3, and OD value at 405 nm was measured using a
standard plate reader. Treatment with 4 resulted in a significant
increase in the activation of caspase −9 and −3 compared to its
parent compound NS. Each point on the graph represents Mean ± SD;
p values of t-test are indicated on top of horizontal bars. n = 3.
Deb et al. BMC Cancer 2014, 14:567 Page 3 of 8
http://www.biomedcentral.com/1471-2407/14/567Apoptosis assay
Following treatment of cells (1.5 × 106 MDA-MB-231
cells/well in a 12-well plate) with naproxen sodium or 4
for two different time points, apoptosis was determined by
“Apo-TRACE Apoptotic Cell Staining Kit” (# CS1110;
Sigma), as per manufacturer’s instruction. Control cells
were treated with DMSO-media. In principle, viable cells
are Apo-TRACE−/PI−, dead or necrotic cells are Apo-
TRACE−/PI+, early apoptotic cells are Apo-TRACE+/PI−,
and late apoptotic cells are Apo-TRACE+/PI+.
Caspase assay
To detect the levels of caspases-3, −8 and −9 in cell lysates
from treated and untreated cells (1.5 × 106 MDA-MB-231
cells/well in a 6-well plate), Caspase Colorimetric Protease
Assay Sampler Kit (# KHZ1001; Life Technologies) was
used as per manufacturer’s protocol. In principle, active
caspase 3, 8 or 9 cleaves the individual fluorogenic sub-
strate to release the fluorochrome, which can be detected
using a microtiter plate reader at 405 nm.Figure 3 Naproxen-derivatives induce cytotoxic killing in two breast
different concentrations of naproxen sodium (NS) and its derivatives for 24
showed an enhanced killing effect on both the cell lines, when comparedCell cycle study
In order to determine the cell cycle phase distribution of
nuclear DNA, cells (1.5 × 106 MDA-MB-231 cells/well in
a 6-well plate) were harvested and fixed in 100% chilled
methanol and permeabilized. Cells were treated with
RNase (10 μl from 2 mg/ml stock) and nuclear DNA
was labeled with PI (125 μg/ml). Cell-cycle phase dis-
tribution was determined on a FACSCalibur using Cell-
Quest software [14]. For each sample, 10,000 events were
acquired for analysis after excluding cell doublets and
clumps by gating. Histogram display of FL2-A (x axis, PI-
fluorescence) versus counts (y axis) has been displayed in
Figure 2.
PGE2 synthesis assay
The amount of secreted PGE2, from treated and untreated
cell (1.5 × 106 MDA-MB-231 cells/well in a 12-well plate)
culture supernatants, was determined using Prostaglandin
E2 EIA kit (Cayman Chemicals, Ann Arbor, MI). The con-
ditioned medium was centrifuged to remove any cells andcancer cell lines. MCF-7 and MDA-MB-231 cells were treated with
h followed by addition of MTT. Except 3, rest of the derivatives
with NS. Each point on the graph represents Mean ± SD. n = 3.
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done according to the manufacturer’s protocol.Cell migration assay
MDA-MB-231 cells were grown to confluency in a 9 cm2
culture plate. A 200 μl sterile pipette tip was used to intro-
duce a scratch followed by treatment with different con-
centrations (1 mM and 3 mM) of naproxen sodium, 4 or
DMSO. Still and/or video images were captured during or
after 22 h to monitor wound closure rate to measure mi-
gration speed and polarity [15].Figure 4 Derivative 4 can induce apoptosis in MDA-MB-231 cells. MD
for 4 h and 24 h, and were stained with the Apo-TRACE cell staining kit fol
an early induction of apoptosis than NS. (Inset showing bright field image of
changes in cell structure upon drug treatment.) At least 3 microscopic fields w
(b) Bar graph representing percentage of live cells. Each point on the graph rStatistical analysis
IC50 was calculated by nonlinear regression analysis using
OriginPro. The mean and SD values were computed using
Microsoft Excel, and GraphPad software was used to cal-
culate p values.
Results and discussion
Enhanced cytotoxic killing is evident by naproxen-derivatives
against MCF-7 and MDA-MB-231 cells
The cytotoxic effect of the synthesized molecules, the
naproxen-derivatives (Figure 1), was first examined in a
preliminary screening using two human breast cancer
cell lines, MCF-7 and MDA-MB-231 cells (Figure 3) and
the overall findings have been summarized in Table 1.
Based on their IC50 values, except 3, rest of the deriva-
tives were found to have a better killing property com-
pared to their parent compound naproxen sodium (NS).
It is of note that although 1 and 2 could exhibit better
killing properties (IC50 ~ 2 mM and ~3 mM, respect-
ively) against the cancer cell lines, they also proved to be
cytotoxic against the mouse macrophage cell line RAW
264.7 [13]. Because macrophages serve as the first line
of defense during tumor establishment [16], a drug mol-
ecule with little to no toxic effect against macrophages
would be advantageous. Keeping these in mind, weA-MB-231 cells were incubated with or without cytotoxic compounds
lowed by fluorescence imaging studies. (a) Cells treated with 4 lead to
control and drug treated MDA-MB-231 cells indicating morphological
ere examined for staining and representative images are shown here.
epresents Mean ± SD. n = 3.
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the two cancer cell lines employed in the study with
minimal adverse effect on RAW 264.7 cell.
Treatment with 4 induces early apoptosis in MDA-MB-231
cells
Because MDA-MB-231 is a highly aggressive cell line com-
pared to MCF-7, we sought to study our compound of
interest in depth using the former one. In order to under-
stand whether the observed cell killing was due to apop-
tosis or necrosis, we looked for Apo-Trace positive cells inFigure 5 Cell cycle arrest in MDA-MB-231 cells is not evident upon tr
cytotoxic compounds for 24 h. Followed by fixation and permeabilizati
was determined by flow cytometric analysis. (b) No significant cell-cycl
point on the graph represents Mean ± SD, p values of t-test are indicatdrug-treated samples. We could detect early apoptotic cells
within the first 4 h of 4 (6 mM) treatment and late apop-
totic cells at a later time point (24 h). Cells treated with NS
at the same concentration could not undergo apoptosis by
4 h and very few apoptotic cells were evident at 24 h time
point (Figure 4).
Naproxen derivative 4 induces caspase-3/9 mediated
apoptosis in MDA-MB-231 cells
Many researchers have commented on the crucial role
of caspase-cascade system in apoptosis, and the role ofeatment with 4. MDA-MB-231 cells were treated with DMSO or
on, the cells were stained with PI. (a) Cell-cycle phase distribution
e arrest in cells treated with either NS or 4 was detected. Each
ed on top of horizontal bars, n = 3.
Figure 6 Derivative 4 inhibits Prostaglandin E2 secretion in
MDA-MB-231 cells. Conditioned medium from 24 h treated or
untreated culture wells were collected and PGE2 levels were
assayed using Prostaglandin E2 EIA kit. At 6 mM concentration,
4 could significantly reduce PGE2 secretion in MDA-MB-231 cells
compared to NS. Each point on the graph represents Mean ± SD,
p values of t-test are indicated on top of horizontal bars. n = 3.
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is well accepted. Treatment with 4 (6 mM) for 6 h resulted
in a significant increase in the activation of caspase −9
and −3 compared to its parent compound NS (Figure 2).
These results suggest that the 4 mediated observed apop-
tosis in MDA-MB-231 cells is due to activation of
caspases-3 and −9. Hence, our study clearly indicates
involvement of the intrinsic pathway [18] of caspase
activity in inducing apoptosis in MDA-MB-231 cells.
Neither NS nor 4 induces cell-cycle arrest in MDA-MB-231
cells
Growing bodies of evidence suggest that molecules, cap-
able of affecting cell cycle progression in cancer cells, can
enhance sensitivity of cancer cells towards anti-cancer
drugs [19,20]. As our study could clearly indicate an
increase in apoptotic cell death after treatment with
4, we carried out cell-cycle analysis to detect any changes
in cell-cycle progression (Figure 5). We failed to no-
tice significant cell-cycle arrest in cells treated with
NS or 4 for 24 h compared to DMSO treated control
cells. However, in drug-treated samples, we could detect
a high percentage of cell population residing in the
hypoploid state, indicating apoptotic cell population.
Hence, both NS and its derivative 4 mediated ob-
served growth inhibitory activity on MDA-MB-231 cells
was not due to cell cycle arrest but due to induction of
apoptosis.
Naproxen derivative 4 inhibits PGE2 synthesis in MDA-MB-231
cells
A hallmark of breast cancer cells is up-regulated COX-2,
which in turn result in an increase in PGE2 synthesis
[21]. As NSAIDs are known to affect COX-2 activity and
reduce COX-2 induced PGE2 synthesis, we wanted to
determine if 4 could also act in the similar fashion. We
checked the level of PGE2 in conditioned cell culture
medium collected from MDA-MB-231 cells after DMSO
or drug-treatment for 24 h. At 6 mM concentration, 4
could significantly reduce PGE2 secretion by MDA-MB-
231 cells compared to NS (Figure 6), confirming 4 to be
a more potent inhibitor of COX-2 mediated PGE2 pro-
duction. The observed phenomenon could be due to in-
hibition of COX-2, as the parent compound Naproxen is
a well known COX inhibitor. This finding might also
establish 4 as a promising candidate in reducing inflam-
mation which is known to play significant role in cancer
progression [22].
Treatment with 4 can slow-down cell-migration rate in
MDA-MB-231cells
After evaluating the effect of 4 in the production of
PGE2, we wanted to test the influence of 4 on the cancer
cell migration as it is now well established that PGE2plays a vital role in the migration of breast cancer cells.
Poor prognosis of breast cancer patients are associated
with secondary tumor formation, thus, any compound
that can intervene with migrational capacity and metasta-
sis of breast cancer cells may have profound impact on
improved survivability of such patients. We opt for MDA-
MB-231 over MCF-7 due to its highly metastatic and mi-
gratory properties compare to the non- metastatic and
poorly migrating MCF-7 cells [21]. Cells treated with NS
for 22 h at a higher concentration (3 mM) covered 66% of
the gap, whereas, 4, at the same concentration and time
point, could cover only 6% of the gap (Figure 7a).
We then opted for a lower dose (1 mM) of drug (NS
and 4) to study dose-dependent migratory inhibition in
the same cell line, and captured time-lapse video images
of treated/untreated cells for duration of 22 h (Figure 7b).
We, then, randomly selected seven time points to calcu-
late the migration speed (Table 2) based on the distance
travelled/h (Figure 7c). The cells, treated with NS, mi-
grated at a speed of 8.5 μm/h whereas, treatment with 4
led to a much slower rate (4.5 μm/h) of migration; al-
most half of the migration speed of NS-treated cells.
These results clearly indicate that 4 could successfully
delay the migration of MDA-MB-231 cells, most prob-
ably by reducing COX-2 derived PGE2 synthesis. Since
migration is the first step towards invasion and metasta-
sis of cancer cells, 4 might as well interfere with the me-
tastasis process. However, further experimentation using
murine cancer-model would be essential to support the
claim.
Figure 7 Treatment with 4 delays migration rate of MDA-MB-231 cells in vitro. A scratch was introduced in the culture dish and the cells
were left treated (3 mM and 1 mM) or untreated for 22 h. Photo micrographic as well as time-lapse video micrographic images were captured to
study relative migration capacity of control or drug treated MDA-MB-231 cells. (a) At 3 mM concentration, cells treated with NS covered 66% of
the gap, whereas, 4, could cover only 6% of the gap. (b) Video micrographic images indicating migration rates of control or treated MDA-MB-231
cells during 22 h. (c) Graph indicating distance travelled/h of control or treated MDA-MB-231 cells during 22 h. Each point on the graph represents
Mean ± SD, p values of t-test are indicated on top of horizontal bars. n = 3.
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Here, we have presented a new peptide based derivative
4 obtained from the NSAID naproxen capable of show-
ing cytotoxic property against two human breast cancer
cell lines and, have also provided brief experimental evi-
dence, supported by literature, to address the underlying
mechanism of action. In summary our studies suggest
that derivative 4 mediated cell-killing is due to an early
induction of apoptotic event followed by activation ofTable 2 In vitro migration speed of control or treated
MDA-MB-231 as determined by scratch wound assay
Drug Treatment (1 mM) Migration speed (μm/h)
Control ~12
NS ~8.83
4 ~5.3intrinsic caspase-cascade at a molecular level, while no sign
of significant cell-cycle arrest was evident. Furthermore, we
have showed that 4 can inhibit PGE2 synthesis and delay
tumor cell migration (in vitro). Since the derivative 4 is
capable of forming hydrogel at room temperature [13]
it can also be employed as the hydrogel drug-delivery
system [23] for sustained release of the anti-cancer agent.
However, it is also important to note the difference in the
IC50 vales of 4 against p53 wild type MCF-7 (~3 mM) and
p53 null MDA-MB-231 (~6 mM) cells. The highly skewed
killing of MCF-7 cells by this compound might indicate
the involvement of p53 mediated apoptotic pathway. One
of the major off target effects of 4 may include p53 targets
such as bax. Further experimentation is needed to eluci-
date these potential off target effects of this novel anti-
cancer compound. Potential limitation of this drug could
be the fact that it may include p53 as one of its targets,
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relatively elevated for p53 muted cancer cells compared to
p53 wild type cancer cells. Overall these studies imply that
peptide based naproxen-derivative 4 can serve as an anti-
cancer agent.
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